Xyz future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Xyz}} | {{Xyz}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{SHH}} | ||
==Overview== | ==Overview== | ||
Revision as of 13:15, 20 April 2018
|
Xyz Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Xyz future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Xyz future or investigational therapies |
|
Risk calculators and risk factors for Xyz future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Overview
MCTD involves milder disease activity than systemic sclerosis and systemic lupus erythematosus. However mortality rates have been reported to be high in MCTD and it is known that organ damage increase over time even though disease activity decreases. Organ damage over time in patients with MCTD should be assessed further in future studies.
Future or Investigational Therapies
- MCTD involves milder disease activity than systemic sclerosis and systemic lupus erythematosus. However mortality rates have been reported to be high in MCTD and it is known that organ damage increase over time even though disease activity decreases. Organ damage over time in patients with MCTD should be assessed further in future studies.